Table 2.
Expression of lncRNAs related to tumor drug resistance in GB tumors
| lncRNA | Expression relative to HB (fold change to 1) | Expression status in GB according to GEPIA2 analysis | Expression status in GB according to literature | |||
|---|---|---|---|---|---|---|
| G108T | G113T | G114T | G116T | |||
| MALAT1 | 0.04 [0.015, 0.064] | 0.28 [> 0.000, 0.6526] | 0.17 [0.090, 0.249] | 0.54 [> 0.000, 1.334] | Downregulated | Expression level dependent on TMZ responsiveness (Chen et al. 2017) |
| CASC2 | 0.05 [0.018, 0.081] | 0.56 [0.019, 1.101] | 0.33 [> 0.000, 0.727] | 1.43 [> 0.000, 3.053] | Differences non-significant | Downregulated (Liao et al. 2017); Dependent on TMZ responsiveness (Jiang et al. 2018) |
| H19 | 0.01 [0.003, 0.016] | 2.02 [0.540, 3.499] | 15.5 [3.82, 27.18] | 1.42 [> 0.000, 3.481] | Upregulated | Upregulated, correlates with TMZ resistance in glioma patients (Jiang et al.2016) |
| TUSC7 | 0.0013 [0.0011, 0.0014] | 0.23 [0.0072, 0.4528] | 0.51 [0.016, 1.003] | 5.51 [> 0.000, 11.124] | Differences non-significant | Negatively correlated to TMZ resistance in GB (Shang et al. 2018) |
| XIST | 0.15 [> 0.000, 0.398] | 0.67 [0.371, 0.968] | 0.0001 [> 0.000, 0.000216] | 1.93 [> 0.000, 5.780] | Differences non-significant | Upregulated (Du et al. 2017; Yao et al. 2015) |
| RP11-838N2.4 | 0.08 [0.055, 0.104] | 0.6 [> 0.000, 1.519] | 0.91 [> 0.000, 2.723] | 29.73 [> 0.000, 67.091] | No data | Correlated with glioma grading and risk of GB relapse (Liu et al. 2016) |
| DLX6-AS1 | 0.54 [> 0.000, 1.185] | 0.06 [> 0.000, 0.123] | 0.22 [0.076, 0.363] | 1.45 [0.940, 1.959] | Downregulated | Upregulated (Li et al. 2019) |
| GLIDR | 0.18 [0.052, 0.307] | 1.99 [0.648, 3.331] | 0.76 [> 0.000, 1.555] | 1.65 [0.138, 3.161] | Differences non-significant | Downregulated (Zhang et al. 2013) |
| MIR210HG | 0.44 [0.026, 0.853] | 0.26 [> 0.000, 0.562] | 4.95 [1.926, 7.973] | 23.65 [> 0.000, 64.439] | Upregulated | Upregulated (Min et al. 2016) |
| SOX2-OT | 0.13 [0.034, 0.225] | 0.58 [0.118, 1.041] | 0.22 [> 0.000, 0.458] | 0.34 [0.005, 0.674] | Upregulated | Upregulated (Su et al. 2017) |
Data exhibited as fold change [mean: 95%CI] in relation to expression level in control human brain; underexpression = fold change < 1; overexpression = fold change > 1
GEPIA2 analysis based on available datasets; comparison of expression data for the163 GB vs 207 normal controls
HB human brain, GB glioblastoma